Hormone Could Improve Diabetes Treatment

Biomarker might predict how type 2 patients will respond to drugs, study shows

THURSDAY, June 25 (HealthDay News) -- A hormone might be an effective biomarker to help improve treatment of type 2 diabetes, U.S. researchers report.

Adiponectin is a metabolic hormone that regulates a number of processes, including glucose regulation and metabolism of fat for energy production. Previous research has shown an association between adiponectin and insulin sensitivity.

Advertisement

Related Stories • Processed Meat May Harm the Heart • More Info Needed on Problems With Insulin Pumps • Whole Grains Take a Bite Out of Type 2 Diabetes Risk Related Videos Reversing Nerve Damage Monitoring Diabetes Patients And Doctors Discuss The I-Port Related Slides Diabetes Thyroid Disease Diabetic Retinopathy Related Encyclopedia • Addison's Disease • Carcinoid Syndrome • Congenital Adrenal Hyperplasia

This new study found that levels of the hormone in patients with type 2 diabetes helped predict how patients responded to certain diabetes drugs. The researchers' analysis of data from several clinical trials revealed that levels of adiponectin in the blood are able to predict activation of receptors called PPARs, which assist the genes that help cells respond to insulin.

The results support the possible use of adiponectin as a biomarker to monitor glucose tolerance and to predict patient response to diabetes drugs called thiazolidinediones.

The study appears in the June 24 online edition of Clinical Pharmacology & Therapeutics.

More information

The U.S. National Institute of Diabetes and Digestive Diseases has more about diabetes.

-- Robert Preidt